The World Market for Vaccines, Antisera, and Other Blood Fractions: A 2024 Global Trade Perspective
This report was created for strategic planners, international executives, and import/export managers who are concerned with the market for vaccines, antisera, and other blood fractions. With the globalization of this market, managers can no longer be contented with a local view. Nor can managers be contented with out-of-date statistics that appear several years after the fact. Professor Philip M. Parker, the Chair Professor of Management Science at INSEAD, has developed a methodology, based on macroeconomic and trade models, to estimate the market for vaccines, antisera, and other blood fractions for those countries serving the world market via exports or supplying from various countries via imports. He does so for the current year based on a variety of key historical indicators and econometric models.
"Vaccines, antisera, and other blood fractions" as a category is defined in this report following the definition given by the United Nations Statistics Division Classification Registry using the Standard International Trade Classification, Revision 3 (SITC, Rev. 3). The SITC code that defines "vaccines, antisera, and other blood fractions" is 54163.
- 1 METHODOLOGY
- 1.1 OUR APPROACH
- 2 THE WORLD MARKET
- 2.1 EXPORTS
- 2.1.1 THE WORLD MARKET: VACCINES, ANTISERA, AND OTHER BLOOD FRACTIONS EXPORT SUPPLIES IN 2024
- 2.2 IMPORTS
- 2.2.1 THE WORLD MARKET: IMPORTED VACCINES, ANTISERA, AND OTHER BLOOD FRACTIONS IN 2024
- 3 EXPORTS
- 3.1 AFRICA: EXPORT SUPPLIES OF VACCINES, ANTISERA, AND OTHER BLOOD FRACTIONS IN 2024
- 3.1.1 EXECUTIVE SUMMARY
- 3.1.2 BOTSWANA
- 3.1.3 CAMEROON
- 3.1.4 EGYPT
- 3.1.5 ESWATINI
- 3.1.6 ETHIOPIA
- 3.1.7 KENYA
- 3.1.8 MALI
- 3.1.9 MAURITIUS
- 3.1.10 MOROCCO
- 3.1.11 NAMIBIA
- 3.1.12 NIGERIA
- 3.1.13 RWANDA
- 3.1.14 SENEGAL
- 3.1.15 SOUTH AFRICA
- 3.1.16 TANZANIA
- 3.1.17 THE CENTRAL AFRICAN REPUBLIC
- 3.1.18 TUNISIA
- 3.1.19 UGANDA
- 3.1.20 ZIMBABWE
- 3.2 ASIA: EXPORT SUPPLIES OF VACCINES, ANTISERA, AND OTHER BLOOD FRACTIONS IN 2024
- 3.2.1 EXECUTIVE SUMMARY
- 3.2.2 BANGLADESH
- 3.2.3 CHINA
- 3.2.4 HONG KONG
- 3.2.5 INDIA
- 3.2.6 INDONESIA
- 3.2.7 JAPAN
- 3.2.8 MALAYSIA
- 3.2.9 NEPAL
- 3.2.10 NORTH KOREA
- 3.2.11 SINGAPORE
- 3.2.12 SOUTH KOREA
- 3.2.13 SRI LANKA
- 3.2.14 TAIWAN
- 3.2.15 THAILAND
- 3.2.16 THE PHILIPPINES
- 3.2.17 VIETNAM
- 3.3 EUROPE: EXPORT SUPPLIES OF VACCINES, ANTISERA, AND OTHER BLOOD FRACTIONS IN 2024
- 3.3.1 EXECUTIVE SUMMARY
- 3.3.2 AUSTRIA
- 3.3.3 BELARUS
- 3.3.4 BELGIUM
- 3.3.5 BOSNIA AND HERZEGOVINA
- 3.3.6 BULGARIA
- 3.3.7 CROATIA
- 3.3.8 CYPRUS
- 3.3.9 DENMARK
- 3.3.10 ESTONIA
- 3.3.11 FINLAND
- 3.3.12 FRANCE
- 3.3.13 GEORGIA
- 3.3.14 GERMANY
- 3.3.15 GREECE
- 3.3.16 HUNGARY
- 3.3.17 ICELAND
- 3.3.18 IRELAND
- 3.3.19 ITALY
- 3.3.20 KAZAKHSTAN
- 3.3.21 LATVIA
- 3.3.22 LITHUANIA
- 3.3.23 LUXEMBOURG
- 3.3.24 MACEDONIA
- 3.3.25 MALTA
- 3.3.26 NORWAY
- 3.3.27 POLAND
- 3.3.28 PORTUGAL
- 3.3.29 ROMANIA
- 3.3.30 RUSSIA
- 3.3.31 SLOVAKIA
- 3.3.32 SLOVENIA
- 3.3.33 SPAIN
- 3.3.34 SWEDEN
- 3.3.35 SWITZERLAND
- 3.3.36 THE CZECH REPUBLIC
- 3.3.37 THE NETHERLANDS
- 3.3.38 THE UNITED KINGDOM
- 3.3.39 UKRAINE
- 3.4 LATIN AMERICA: EXPORT SUPPLIES OF VACCINES, ANTISERA, AND OTHER BLOOD FRACTIONS IN 2024
- 3.4.1 EXECUTIVE SUMMARY
- 3.4.2 ARGENTINA
- 3.4.3 BRAZIL
- 3.4.4 CHILE
- 3.4.5 COLOMBIA
- 3.4.6 COSTA RICA
- 3.4.7 ECUADOR
- 3.4.8 EL SALVADOR
- 3.4.9 GUATEMALA
- 3.4.10 HONDURAS
- 3.4.11 MEXICO
- 3.4.12 NICARAGUA
- 3.4.13 PANAMA
- 3.4.14 PARAGUAY
- 3.4.15 PERU
- 3.4.16 URUGUAY
- 3.4.17 VENEZUELA
- 3.5 NORTH AMERICA & THE CARIBBEAN: EXPORT SUPPLIES OF VACCINES, ANTISERA, AND OTHER BLOOD FRACTIONS IN 2024
- 3.5.1 EXECUTIVE SUMMARY
- 3.5.2 BERMUDA
- 3.5.3 CANADA
- 3.5.4 CUBA
- 3.5.5 ST. KITTS AND NEVIS
- 3.5.6 THE DOMINICAN REPUBLIC
- 3.5.7 THE UNITED STATES
- 3.6 OCEANIA: EXPORT SUPPLIES OF VACCINES, ANTISERA, AND OTHER BLOOD FRACTIONS IN 2024
- 3.6.1 EXECUTIVE SUMMARY
- 3.6.2 AUSTRALIA
- 3.6.3 NEW ZEALAND
- 3.7 THE MIDDLE EAST: EXPORT SUPPLIES OF VACCINES, ANTISERA, AND OTHER BLOOD FRACTIONS IN 2024
- 3.7.1 EXECUTIVE SUMMARY
- 3.7.2 AFGHANISTAN
- 3.7.3 ARMENIA
- 3.7.4 IRAN
- 3.7.5 IRAQ
- 3.7.6 ISRAEL
- 3.7.7 JORDAN
- 3.7.8 LEBANON
- 3.7.9 PAKISTAN
- 3.7.10 SAUDI ARABIA
- 3.7.11 SYRIA
- 3.7.12 THE UNITED ARAB EMIRATES
- 3.7.13 TURKEY
- 3.7.14 UZBEKISTAN
- 4 IMPORTS
- 4.1 AFRICA: VACCINES, ANTISERA, AND OTHER BLOOD FRACTIONS IMPORTS IN 2024
- 4.1.1 EXECUTIVE SUMMARY
- 4.1.2 ALGERIA
- 4.1.3 BENIN
- 4.1.4 BOTSWANA
- 4.1.5 BURKINA FASO
- 4.1.6 BURUNDI
- 4.1.7 CAMEROON
- 4.1.8 CAPE VERDE
- 4.1.9 COTE D'IVOIRE
- 4.1.10 EGYPT
- 4.1.11 ETHIOPIA
- 4.1.12 GUINEA
- 4.1.13 MADAGASCAR
- 4.1.14 MALAWI
- 4.1.15 MAURITANIA
- 4.1.16 MAURITIUS
- 4.1.17 MOROCCO
- 4.1.18 MOZAMBIQUE
- 4.1.19 NAMIBIA
- 4.1.20 NIGER
- 4.1.21 NIGERIA
- 4.1.22 RWANDA
- 4.1.23 SENEGAL
- 4.1.24 SOUTH AFRICA
- 4.1.25 TANZANIA
- 4.1.26 THE CENTRAL AFRICAN REPUBLIC
- 4.1.27 THE DEMOCRATIC REPUBLIC OF THE CONGO
- 4.1.28 UGANDA
- 4.1.29 ZAMBIA
- 4.1.30 ZIMBABWE
- 4.2 ASIA: VACCINES, ANTISERA, AND OTHER BLOOD FRACTIONS IMPORTS IN 2024
- 4.2.1 EXECUTIVE SUMMARY
- 4.2.2 BRUNEI
- 4.2.3 CHINA
- 4.2.4 HONG KONG
- 4.2.5 INDIA
- 4.2.6 INDONESIA
- 4.2.7 JAPAN
- 4.2.8 MACAU
- 4.2.9 MALAYSIA
- 4.2.10 MONGOLIA
- 4.2.11 NEPAL
- 4.2.12 SINGAPORE
- 4.2.13 SOUTH KOREA
- 4.2.14 SRI LANKA
- 4.2.15 TAIWAN
- 4.2.16 THAILAND
- 4.2.17 THE MALDIVES
- 4.2.18 THE PHILIPPINES
- 4.2.19 VIETNAM
- 4.3 EUROPE: VACCINES, ANTISERA, AND OTHER BLOOD FRACTIONS IMPORTS IN 2024
- 4.3.1 EXECUTIVE SUMMARY
- 4.3.2 ALBANIA
- 4.3.3 ANDORRA
- 4.3.4 AUSTRIA
- 4.3.5 BELARUS
- 4.3.6 BELGIUM
- 4.3.7 BOSNIA AND HERZEGOVINA
- 4.3.8 BULGARIA
- 4.3.9 CROATIA
- 4.3.10 CYPRUS
- 4.3.11 DENMARK
- 4.3.12 ESTONIA
- 4.3.13 FINLAND
- 4.3.14 FRANCE
- 4.3.15 GEORGIA
- 4.3.16 GERMANY
- 4.3.17 GREECE
- 4.3.18 HUNGARY
- 4.3.19 ICELAND
- 4.3.20 IRELAND
- 4.3.21 ITALY
- 4.3.22 KAZAKHSTAN
- 4.3.23 LATVIA
- 4.3.24 LITHUANIA
- 4.3.25 LUXEMBOURG
- 4.3.26 MACEDONIA
- 4.3.27 MALTA
- 4.3.28 MOLDOVA
- 4.3.29 NORWAY
- 4.3.30 POLAND
- 4.3.31 PORTUGAL
- 4.3.32 ROMANIA
- 4.3.33 RUSSIA
- 4.3.34 SLOVAKIA
- 4.3.35 SLOVENIA
- 4.3.36 SPAIN
- 4.3.37 SWEDEN
- 4.3.38 SWITZERLAND
- 4.3.39 THE CZECH REPUBLIC
- 4.3.40 THE NETHERLANDS
- 4.3.41 THE UNITED KINGDOM
- 4.3.42 UKRAINE
- 4.4 LATIN AMERICA: VACCINES, ANTISERA, AND OTHER BLOOD FRACTIONS IMPORTS IN 2024
- 4.4.1 EXECUTIVE SUMMARY
- 4.4.2 ARGENTINA
- 4.4.3 BELIZE
- 4.4.4 BOLIVIA
- 4.4.5 BRAZIL
- 4.4.6 CHILE
- 4.4.7 COLOMBIA
- 4.4.8 ECUADOR
- 4.4.9 EL SALVADOR
- 4.4.10 GUATEMALA
- 4.4.11 GUYANA
- 4.4.12 HONDURAS
- 4.4.13 MEXICO
- 4.4.14 NICARAGUA
- 4.4.15 PANAMA
- 4.4.16 PARAGUAY
- 4.4.17 PERU
- 4.4.18 SURINAME
- 4.4.19 URUGUAY
- 4.5 NORTH AMERICA & THE CARIBBEAN: VACCINES, ANTISERA, AND OTHER BLOOD FRACTIONS IMPORTS IN 2024
- 4.5.1 EXECUTIVE SUMMARY
- 4.5.2 ANTIGUA AND BARBUDA
- 4.5.3 ARUBA
- 4.5.4 BARBADOS
- 4.5.5 BERMUDA
- 4.5.6 CANADA
- 4.5.7 GREENLAND
- 4.5.8 JAMAICA
- 4.5.9 THE BAHAMAS
- 4.5.10 THE DOMINICAN REPUBLIC
- 4.5.11 THE UNITED STATES
- 4.6 OCEANIA: VACCINES, ANTISERA, AND OTHER BLOOD FRACTIONS IMPORTS IN 2024
- 4.6.1 EXECUTIVE SUMMARY
- 4.6.2 AUSTRALIA
- 4.6.3 FIJI
- 4.6.4 FRENCH POLYNESIA
- 4.6.5 NEW CALEDONIA
- 4.6.6 NEW ZEALAND
- 4.6.7 PALAU
- 4.6.8 TONGA
- 4.7 THE MIDDLE EAST: VACCINES, ANTISERA, AND OTHER BLOOD FRACTIONS IMPORTS IN 2024
- 4.7.1 EXECUTIVE SUMMARY
- 4.7.2 ARMENIA
- 4.7.3 AZERBAIJAN
- 4.7.4 BAHRAIN
- 4.7.5 ISRAEL
- 4.7.6 JORDAN
- 4.7.7 KUWAIT
- 4.7.8 LEBANON
- 4.7.9 OMAN
- 4.7.10 PAKISTAN
- 4.7.11 QATAR
- 4.7.12 TURKEY
- 4.7.13 YEMEN
- 5 DISCLAIMERS, WARRANTIES, AND USER AGREEMENT PROVISIONS
- 5.1 DISCLAIMERS & SAFE HARBOR
- 5.2 ICON GROUP INTERNATIONAL, INC. USER AGREEMENT PROVISIONS
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook